Comparison of distress in breast cancer survivors treated with different adjuvant endocrine therapies: a single-centre cross-sectional study

References

• Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–527. doi: 10.1001/jamaoncol.2015.0735
   PubMed Web of Science ®Google Scholar
• Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048. doi: 10.1093/jnci/djv048
   PubMed Web of Science ®Google Scholar
• Aukst-Margetić B, Jakovljević M, Margetić B, et al. Religiosity, depression and pain in patients with breast cancer. Gen Hosp Psychiatry. 2005;27:250–255. doi: 10.1016/j.genhosppsych.2005.04.004
   PubMed Web of Science ®Google Scholar
• Burgess C, Cornelius V, Love S, et al. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ. 2005;330(7493):702. doi: 10.1136/bmj.38343.670868.D3
   PubMed Web of Science ®Google Scholar
• Lee MS, Love SB, Mitchell JB, et al. Mastectomy or conservation for early breast cancer: psychological morbidity. Eur J Cancer. 1992;28A(8–9):1340–1344. doi: 10.1016/0959-8049(92)90514-3
   Web of Science ®Google Scholar
• Hughson AV, Cooper AF, McArdle CS, et al. Psychological impact of adjuvant chemotherapy in the first two years after mastectomy. Br Med J (Clin Res Ed). 1986;293(6557):1268–1271. doi: 10.1136/bmj.293.6557.1268
   Web of Science ®Google Scholar
• Moyer A, Salovey P. Predictors of social support and psychological distress in women with breast cancer. J Health Psychol. 1999;4:177–191. doi: 10.1177/135910539900400212
   PubMedGoogle Scholar
• Wang F, Liu J, Liu L, et al. The status and correlates of depression and anxiety among breast-cancer survivors in eastern China: a population-based, cross-sectional case-control study. BMC Public Health. 2014;14:438. doi: 10.1186/1471-2458-14-438
   Web of Science ®Google Scholar
• Kim SH, Son BH, Hwang SY, et al. Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage. 2008;35:644–655. doi: 10.1016/j.jpainsymman.2007.08.012
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–219. doi: 10.1056/NEJMoa1604700
   PubMed Web of Science ®Google Scholar
• Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract. 2007;61:2051–2063. doi: 10.1111/j.1742-1241.2007.01587.x
   PubMed Web of Science ®Google Scholar
• Banerjee S, Smith IE, Folkerd L, et al. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol. 2005;16:1632–1638. doi: 10.1093/annonc/mdi322
   PubMed Web of Science ®Google Scholar
• Giese-Davis J, Waller A, Carlson LE, et al. Screening for distress, the 6th vital sign: common problems in cancer outpatients over one year in usual care: associations with marital status, sex, and age. BMC Cancer. 2012;12:448. doi: 10.1186/1471-2407-12-441
   Web of Science ®Google Scholar
• Gómez-Campelo P, Bragado-Álvarez C, Hernández-Lloreda MJ. Psychological distress in women with breast and gynecological cancer treated with radical surgery. Psychooncology. 2014;23:459–466. doi: 10.1002/pon.3439
   PubMed Web of Science ®Google Scholar
• Mehnert A, Koch U. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res. 2008;64:383–391. doi: 10.1016/j.jpsychores.2007.12.005
   PubMed Web of Science ®Google Scholar
• Friedman LC, Kalidas M, Elledge R, et al. Optimism, social support and psychosocial functioning among women with breast cancer. Psychooncology. 2006;15:595–603. doi: 10.1002/pon.992
   PubMed Web of Science ®Google Scholar
• Brunet J, Love C, Ramphal R, et al. Stress and physical activity in young adults treated for cancer: the moderating role of social support. Support Care Cancer. 2014;22:689–695. doi: 10.1007/s00520-013-2023-0
   PubMed Web of Science ®Google Scholar
• Tralongo P, Di Mari A, Ferrau’ F. Cognitive impairment, aromatase inhibitors, and age. J Clin Oncol. 2005;23:4243. doi: 10.1200/JCO.2005.01.1304
   PubMed Web of Science ®Google Scholar
• Schilder CM, Schagen SB. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature. Minerva Ginecol. 2007;59:387–401.
   PubMedGoogle Scholar
• Suzuki S, Brown CM, Dela Cruz CD, et al. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci USA. 2007;104:6013–6018. doi: 10.1073/pnas.0610394104
   PubMed Web of Science ®Google Scholar
• Wise PM. Estrogen therapy: does it help or hurt the adult and aging brain? Insights derived from animal models. Neuroscience. 2006;138:831–835. doi: 10.1016/j.neuroscience.2005.08.046
   PubMed Web of Science ®Google Scholar
• Moura PJ, Petersen SL. Estradiol acts through nuclear- and membrane-initiated mechanisms to maintain a balance between GABAergic and glutamatergic signaling in the brain: implications for hormone replacement therapy. Rev Neurosci. 2010;21:363–380. doi: 10.1515/REVNEURO.2010.21.5.363
   PubMed Web of Science ®Google Scholar
• Fontein DB, Seynaeve C, Hadji P, et al. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol. 2013;31(31):2257–2264. doi: 10.1200/JCO.2012.45.3068
   Web of Science ®Google Scholar
• Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295:2742–2751. doi: 10.1001/jama.295.23.joc60075
   PubMed Web of Science ®Google Scholar
• Chen D, Wu CF, Shi B, et al. Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol Biochem Behav. 2002;71(1–2):269–276. doi: 10.1016/S0091-3057(01)00656-6
   Web of Science ®Google Scholar
• Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94:592–597. doi: 10.1093/jnci/94.8.592
   PubMed Web of Science ®Google Scholar
• Jenkins V, Atkins L, Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur J Cancer. 2007;43:1342–1347. doi: 10.1016/j.ejca.2007.03.023
   PubMed Web of Science ®Google Scholar
• Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61–66. doi: 10.1002/pon.709
   PubMed Web of Science ®Google Scholar
• Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology. 2009;18:811–821. doi: 10.1002/pon.1453
   PubMed Web of Science ®Google Scholar
• Schilder CM, Eggens PC, Seynaeve C, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol. 2009;48:76–85. doi: 10.1080/02841860802314738
   PubMed Web of Science ®Google Scholar
• Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28:1294–1300. doi: 10.1200/JCO.2008.21.3553
   PubMed Web of Science ®Google Scholar
• Rhun EL, Delbeuck X, Lefeuvre-Plesse C, et al. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Res Treat. 2015;152:569–580. doi: 10.1007/s10549-015-3493-1
   Web of Science ®Google Scholar
• Takei H, Ohsumi S, Shimozuma K, et al. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: national surgical adjuvant study of breast cancer 04 (N-SAS BC 04). Breast Cancer Res Treat. 2012;133:227–236. doi: 10.1007/s10549-011-1943-y
   PubMed Web of Science ®Google Scholar
• Ohsumi S, Shimozuma K, Ohashi Y, et al. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1–4 years: N-SAS BC 03. Breast Cancer Res Treat. 2011;127:143–152. doi: 10.1007/s10549-011-1400-y
   PubMed Web of Science ®Google Scholar
• Archer JS. NAMS/solvay resident essay award. Relationship between estrogen, serotonin, and depression. Menopause. 1999;6(Spring):71–78.
   Google Scholar
• Shariff S, Cumming CE, Lees A, et al. Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect? Ann N Y Acad Sci. 1995;761:365–368. doi: 10.1111/j.1749-6632.1995.tb31394.x
   PubMed Web of Science ®Google Scholar